【摘要】 目的探讨紫杉醇脂质体联合替吉奥新辅助化疗治疗进展期胃癌疗效。方法 32例病理诊断确诊为Ⅱ~Ⅲ期进展期胃癌患者,未接受过抗肿瘤治疗,无严重心肺疾病。采用DS方案:紫杉醇脂质体125mg/m2静脉滴注,d 1;替吉奥胶囊,每次60 mg/m2,Bid,口服,d 1~14;每21d重复,共3~4个周期,评估疗效并观察不良反应。结果 32例患者中完全缓解(CR)1例,部分缓解(PR)28例,稳定(SD)2例,进展(PD)1例,客观缓解率(OR)为90.6%(29/32)。发生骨髓抑制13例(40.62%),胃肠道反应16例(50%)。均接受了根治性切除,无围手术期死亡病例。结论紫杉醇脂质体联合替吉奥新辅助化疗治疗进展期胃癌安全可行。更多还原

【Abstract】 Objective To assess the efficacy and toxicity of liposome-paclitaxel and S-1combination therapy for advanced gastric cancer.Methods The chemotherapy regime was 125mg/m2 liposome-paclitaxel given on day 1,combined with S-1 60mg/m2 twice a day on days 1-14,taking 3weeks as one treatment cycle.The patients continued to be treated until receiving three or four cycles or until developing neither progressive disease nor untolerated toxicity.Resaults The total 32 patients with advanced gastric cancer were enrolled in primary treatment,with pathological diagnosis and staging ofⅡ-Ⅲ period.Meanwhile,all patients received radical resection without perioperative death.The results showed 1case achieved CR,28 cases achieved PR with an ORR of 90.6%.2case achieved SD,2cases achieved PD.The hematological toxicities were neutropenia which occurred in 13(40.62%).Nausea,vomiting occurred in 16(50%)patients.Conclusions The combination regimen of liposome-paclitaxel and S-1is effective and well tolerated for patients with advanced gastric carcinoma,especially for primary treatment cases.更多还原